Clinical Trials Logo

Clinical Trial Summary

Radiotherapy is one of the main treatments for malignant tumors, and according to authoritative estimates, about 70% of patients with malignant tumors should receive radiotherapy. However, radiation resistance limits its application and clinical curative effect. To find suitable radiation resistance markers and identify patients with radiation resistance, early part of the patients with appropriate radiotherapy sensitization agent or choose other more efficient and low toxicity of treatment, for improving the prognosis of patients, improve the quality of survival is of great significance, it is also the difficult point in the present study. However, there are no effective biomarkers to predict radiosensitivity. Through our previous basic research and analysis of clinical tumor tissues, we have found that the low expression of copper metabolism domain protein 10 (COMMD10) is associated with radioresistance, and COMMD10 is an effective marker for predicting radiosensitivity. We planned to conduct a single-center, prospective cohort study to verify the reliability of COMMD10 as a predictive marker for radiosensitivity in pan-cancer patients.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06165224
Study type Observational
Source Nanfang Hospital, Southern Medical University
Contact Jian Guan, M.D.
Phone +86-13632102247
Email guanjian5461@163.com
Status Recruiting
Phase
Start date December 1, 2023
Completion date June 30, 2025

See also
  Status Clinical Trial Phase
Recruiting NCT03219593 - Apatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric Cancer Phase 2
Active, not recruiting NCT04681040 - Risk Stratification of COVID-19 Using Urine Biomarkers
Recruiting NCT05372172 - Tennessee Alzheimer's Project
Recruiting NCT06096766 - the Correlation Between Ovarian Function and Serum Biomarkers
Completed NCT04103632 - Screening and Diagnosing Exercise-induced Bronchoconstriction in Recreational Young Athletes (12-18 y) N/A
Completed NCT01159730 - Study to Assess the Safety and Efficacy of Multiple Doses of VB-201 on Biomarkers Phase 2
Completed NCT04507724 - The Use of Biochemical Analyzes to Monitor the Development of Wounds
Completed NCT06338111 - Can we Improve Mortality Prediction in Patients With Sepsis in the Emergency Department
Active, not recruiting NCT05027165 - Prospective Evaluation of Immunological, Molecular-genetic, Image-based and Microbial Analyzes to Characterize Tumor Response and Control in Patients With Inoperable Stage III NSCLC Treated With Chemoradiotherapy Followed by Consolidation Therapy With Durvalumab
Not yet recruiting NCT02931136 - Early Diagnosis and Early Treatment of Alzheimer's Disease Based on Senile Plaque Imaging Phase 4
Not yet recruiting NCT03739892 - Biomarkers to Predict Gain From Therapy in Motor Stroke N/A
Recruiting NCT03801681 - ARrhythmias in MYocarditis
Recruiting NCT05372965 - The Effects of Smoking on miRNA-223 Before-After Non-Surgical Periodontal Therapy in Patients With Stage-3, Grade-B Periodontitis N/A
Completed NCT04772495 - miRNA Biomarkers in Multiple Sclerosis
Active, not recruiting NCT06178692 - Validation Study of a Serum-miRNA Signature in Glioma Patients.
Recruiting NCT04931537 - Screening and Application Research of Early Diabetic Nephropathy Markers Based on Lipidomics.
Recruiting NCT05090410 - Efficacy and Safety of Selective JAK 1 Inhibitor Filgotinib in Active Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate Phase 3
Not yet recruiting NCT05764356 - Imapct of bioMarkers on Pharmacodynamics and Bleeding Risk of Direct Oral AntiCoagulants and Ticagrelor Study II
Recruiting NCT02201446 - The Role of Circulating Soluble CD74 in Acute Lung Injury N/A
Not yet recruiting NCT05752890 - A Novel Biomarker for Response and Prognosis of HBV-related Hepatocellular Carcinoma